Figure 10.

Antibody binding to PBMC populations in a resting state or activated state. Data is displayed as average median fluorescent intensity (MFI) ± SD (N = 5). Ratio of activated divided by resting MFI is displayed above bars for activated cells. PBMC were examined either in a resting state immediately following isolation or after activation using CD28/CD3 beads for 48 h. Only antibodies with relevant expression level (mean MFI over 50) were plotted for the respective cell type. Data were analyzed using paired two-sided t test comparing pre- and post-activation MFI (*p < 0.05, **p < 0.01). A significant increase in siplizumab binding to T (19-fold; p = 0.0083) and NK cells (five-fold; p = 0.0013) was measured upon PBMC activation. Alemtuzumab binding to T (0.3-fold; p = 0.0032) and B (0.2-fold; p = 0.0045) cells declined significantly. Lastly, rATG binding to T (0.7-fold; p = 0.0188) and B (0.5-fold; p = 0.0050) cells decreased significantly following activation.